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Abstract
Backgroundandobjective: Idiopathic pulmonary fibrosis (IPF) has a poor prognosis in general; however, it is heterogeneous to
detect relative biomarkers for predicting the disease progression. Serum biomarkers can be conveniently collected to detect and help
to differentially diagnose IPF and predict IPF prognosis. This meta-analysis aimed to evaluate the use of serum surfactant proteins A
and D (SP-A and SP-D) for differential diagnosis and prognosis of IPF.
Methods: Relevant articles were searched in PubMed, Embase, and Chinese National Knowledge Infrastructure databases and
reviewed by 2 independent readers. Standard mean difference (SMD) and 95% confidence interval (CI) were calculated to assess the
difference in serum levels of SP-A/D among patients with IPF, when compared to patients with non-IPF interstitial lung disease (ILD),
pulmonary infection, and healthy control. Hazard ratio (HR) and 95% CI were used to compare the relative risk of mortality.
Results: Twenty-one articles (totalling 1289 IPF patients) were included in final meta-analysis. Serum SP-A levels were significantly
higher in patients with IPF than in patients with non-IPF ILD (SMD: 1.108 [0.584, 1.632], P< .001), or pulmonary infection (SMD:
1.320 [0.999, 1.640], P< .001) and healthy controls (SMD: 2.802 [1.901, 3.702], P< .001). There was no significant difference in
serum SP-D levels between patients with IPF and those with non-IPF ILD patients (SMD: 0.459 [0.000, 0.919], P= .050). Serum
SP-D levels were significantly higher in patients with IPF than in patients with pulmonary infection (SMD: 1.308 [0.813, 1.803],
P< .001) and healthy controls (SMD: 2.235 [1.739, 2.731], P< .001). Risk of death in patients with IPF and elevated serum SP-A was
increased 39% compared to patients with low SP-A groups. Elevated SP-D increased risk by 111%when compared to low SP-D. In
acute exacerbation of IPF, serum SP-A/D were higher than those in stable stage. The comparisons and prognosis might be different
in Asian and Caucasian patients.
Conclusions: Serum SP-A/D detection might be useful for differential diagnosis and prediction of survival in patients with IPF.
Abbreviations: 95%CI = 95% confidence interval, AE = acute exacerbation, AHP = acute hypersensitivity pneumonitis, ARDS =
acute respiratory distress syndrome, ATS = American Thoracic Society, CBD = chronic beryllium disease, CCL18 = CC-chemokine
ligand 18, CHP = chronic hypersensitivity pneumonitis, CNKI = Chinese National Knowledge Infrastructure, COPD = chronic
obstructive pulmonary disease, CPI = composite physiologic index, CRP = clinical, radiological, and physiological, CTD-IP =
connective tissue disease-associated interstitial pneumonia, CVD-IP = collagen vascular disease-associated interstitial pneumonia,
Dlco = diffusing capacity of the lung for carbon monoxide, FEV1 = forced expiratory volume in 1 second, FVC = forced vital capacity,
GAP = gender, age, and two lung physiology variables (FVC and Dlco), HR = hazard ratio, HRCT = high-resolution computed
tomography, ILD = interstitial lung disease, I-NSIP = idiopathic non-specific interstitial pneumonia, IPF = idiopathic pulmonary
fibrosis, KL-6 = Krebs von den Lungen-6, MMP-7 = matrix metalloproteinase-7, PAP = pulmonary alveolar proteinosis, PSS =
progressive systemic sclerosis, SMD = standard mean difference, SP-A = surfactant protein-A, SP-D = surfactant protein-D, SSc-
ILD = scleroderma-associated interstitial lung disease, UIP = usual interstitial pneumonia.
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1. Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive
fibrotic interstitial lung disease (ILD) of unknown etiology.[1]
Several studies have indicated that the worldwide incidence of IPF
seems to be increasing, especially in Europe and North
America.[2] IPF is histologically characterized by the usual
interstitial pneumonia (UIP) pattern. True UIP patterns are also
found in rheumatoid lung, asbestosis, and, rarely, in sarcoido-
sis.[3] The primary diagnostic method of IPF in current clinical
practice is the high-resolution computed tomography (HRCT),
lung biopsy.[4] Incorporating with noninvasive biomarkers (eg,
matrix metalloproteinase-7 [MMP7], surfactant protein-D [SP-
D]) would provide additional evidence for HRCT and clinical
history when distinguish IPF from other ILDs, and they may have
the ability to predict risk for acute exacerbation (AE) of IPF
patients.[5]
The median survival of patients with IPF is 3 years and the 5-
year survival rate is 20% to 40%.[6,7] Pathologist features,[8]
clinical parameters,[9,10] and prediction models,[11,12] including
lung function test, the 6-minute walk test, and the clinical,
radiological, and physiological (CRP) scoring system, have been
used as prognostic tools. However, since the clinical course of
individual patients is highly variable and unpredictable, these
physiologic parameters have limitations.[13] Alternatively, non-
invasive biomarkers may be helpful in identifying patients with
IPF and predicting long-term outcome.
Type II counterproductive molecules, Krebs von den Lungen-6
(KL-6), surfactant protein-A (SP-A), SP-D, MMP-7, and CC-
cheekiness Gilligan 18 (CCL18) have emerged as potential
diagnostic and prognostic biomarkers of IPF.[14] SP-A and SP-D
are hydrophobic, collagen-containing calcium-dependent lectins,
with a range of nonspecific immune functions at pulmonary and
cardiopulmonary sites.[15] SP-A and SP-D play crucial roles in the
pulmonary immune response, and are secreted by type II
pneumocytes, nonciliated bronchiolar cells, submucosal glands,
and epithelial cells of other respiratory tissues, including the
trachea and bronchi. SP-D is important in maintaining pulmo-
nary surface tension, and is involved in the organization, stability,
and metabolism of lung parenchyma.[16]
Serum SP-A and SP-D have been identified as biomarkers for
pulmonary diseases, including acute respiratory distress syn-
drome (ARDS),[17] chronic obstructive pulmonary disease
(COPD),[18] and progressive systemic sclerosis (PSS).[19] Previous
studies had reported that serum SP-A and/or SP-D were
significantly different from IPF and some non-IPF ILD patients
(eg, rheumatoid arthritis–associated ILD).[5] Meanwhile, SP-A
and SP-D levels in BALF may also play a role in differential
diagnosis from IPF and other ILDs (eg, sarcoidosis)[20] and
predicting survival in IPF patients.[21] In IPF patients, serum SP-A
or SP-D also plays helpful roles in differential diagnosis[22] as well
as predicting prognosis.[14] Before this study, the potential role of
serum SP-A and SP-D as diagnostic and prognostic biomarkers in
patients with IPF had not been studied by meta-analysis. The goal
of this study was to evaluate the role of SP-A and SP-D in the
diagnosis and prognosis of IPF.
2. Materials and methods
2.1. Search strategy and ethics permission
In March 2017, we performed systematic searches in PubMed,
EMBASE, and the Chinese National Knowledge Infrastructure
(CNKI). We used the following search terms: “Surfactant
protein” or “SP” and “Idiopathic pulmonary fibrosis” or
“IPF” or “Interstitial lung disease” or “Pulmonary fibrosis.”
We also identified relevant publications by reviewing the
reference of the search results. The meta-analysis was approved
by the Ethics Committee of the Xijing Hospital, the First Affliated
Hospital of the Fourth Military Medical University.
2.2. Inclusion and exclusion criteria
Included studies met the following criteria: SP-A and/or SP-D
were evaluated in human subjects for the differential diagnosis
and prognosis of IPF. In comparison part, patients with IPF were
compared to at least one reference group (non-IPF patients or
healthy subjects). Studies were written in English or Chinese. A
definitive diagnosis of IPF was evident by clinical features, chest
HRCT, laboratory findings, and/or surgical lung biopsy. Data,
for example, serum levels of SP-A and SP-D, and hazard ratios
(HRs), were available from the reviewed articles. In addition, for
inclusion in the prognostic evaluation of SP-A/SP-D in patients
with IPF, studies had to have a defined patient follow-up
schedule, and include death as an endpoint. Studies were
excluded if the data were unavailable after attempts to contact
author.
2.3. Data extraction and quality assessment
Two reviewers independently screened titles and abstracts for
potentially eligible articles. Full texts of articles were obtained,
and 2 reviewers independently determined eligibility. Discrep-
ancies were resolved by a discussion or with a third reviewer. For
every eligible study, we extracted the following information: first
author, year of publication, number and sex of patients with IPF,
patient smoking history, study endpoints, study methods, and
epidemiological study methods. When the association between
SP-A/SP-D and IPF mortality was studied, cutoff values for SP-A
and SP-D were also collected. When study data for meta-analysis
were not available in the article, we attempted to contact author
(s) to obtain original data. Some original data were not available.
In this case, we derived mean and standard deviation using
median and range from graphs and curve diagrams, according to
the method recommended by Hozo et al.[23] In one case, the
relative risk of mortality data was presented as Kaplan–Meier
curves, not HR and 95% confidence interval (CI).[24] In this case,
we calculated the HR and 95% CI according to the method
described by Parmar et al.[25] In the analysis of the association of
SP-A/SP-D with death of patients with IPF, there was an overlap
of subjects in the studies of Greene et al.[26] and Kinder et al.[27].
To avoid sampling bias, we included only the Greene et al.’s[26]
study in the analysis.
We used Newcastle–Ottawa quality assessment scale of case
control studies to evaluate the quality of these studies.[28] A study
could be awarded amaximum of one star for each numbered item
within the Selection and Exposure categories. A maximum of 2
stars could be given for comparability. A study with>5 stars was
included in the meta-analysis.
2.4. Statistical analysis
Statistical analyses were conducted using STATA software (Stata
Corp, TX, version 12.0). All tests were 2-tailed with the
significance level set at P< .05. For analyses of SP-A/SP-D as
diagnostic and prognostic biomarkers, Cochran’sQ test was used
to assess between-study heterogeneity. Heterogeneity was
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presented in the form of the inconsistency index, I2, ranging from
0% to 100%.[29] To assess heterogeneity, the value of I2 was
divided into 3 groups: <25%, 25% to 75%, and >75%,
corresponding to low, moderate, and high heterogeneity. If
statistical heterogeneity existed, the potential causes were
estimated using sensitivity and subgroup analysis. A random-
effect model was applied to reduce the effect of heterogeneity. To
estimate the potential publication bias, we used a funnel plot and
Egger’s test. An asymmetric funnel plot and a P< .05 on the
Egger’s test identified the existence of publication bias.
When assessing the diagnostic effect of SP-A/SP-D, we treated
the biomarkers as continuous, and gave an estimate of the
combined overall effect size utilizing standard mean difference
(SMD) in the random-effects model. For the evaluation of SP-A/
SP-D as prognostic biomarkers of mortality, we used theZ test to
test the pooled HR, and presented both a Z and P value. We
compared the weight of the individual article in influencing the
pooled HR, and the 95% CI. We also did subgroups analysis,
stratified by race, for both diagnostic and prognostic analysis.
3. Results
3.1. Study inclusion, characteristics, and study quality
We identified articles from three databases: PubMed (n=1353),
EMBASE (n=1230), and CNKI (n=305). Nine hundred and
ninety duplicate articles were removed. We excluded 1877
articles that failed to meet the inclusion criteria. A final group of
21 articles met the eligibility criteria[5,14,22,24,26,30–45] (Fig. 1).
Seven of 21 articles evaluated the prognosis of IPF as an outcome
and the observed endpoint was death (Table 1). Eighteen studies
compared the serum level of SP-A/SP-D in patients with IPF to
patients with non-IPF ILD or pulmonary infection, or healthy
controls. All 21 articles were retrospective studies, and none of
these studies reported blindness. No relevant prospective studies
or large-scale meta-analyses were identified. The main character-
istics of the 21 articles are summarized in Table 1. A total of 1289
patients with IPF were included for analyses. The majority of
patients (>58%) were Asian. The date of publication ranged
from 1992 to 2016. Data reflecting severity included FEV1%
predicted, FVC% predicted, and DLco% predicted. DLco%
predicted values varied from 39.1% to 74.9%. The number of
male patients was greater than the number of female patients.
According to study quality assessment criteria (Supplemental
Table 1, http://links.lww.com/MD/B723), the study participation
was adequate and the baseline study sample was completely
delineated in all included articles. Every study that assessed the
prognostic effect of SP-A/SP-D included patient follow-up. All
studies assessed SP-A and (or) SP-D levels; however, different
cutoff values were used, as described in Table 1. SP-A cutoff
values ranged from 53 to 83.5 except Papaioannou’s (280), and
SP-D cutoff values ranged from 225 to 287 except Barlo’s (460).
Figure 1. PRISMA processing map: 2888 publications identified in search strategy (PubMed 1353, EMBASE 1230, CNKI 305). After screening and eligibility
process, only 21 articles met the including criteria and were included in ultimate analysis.
Wang et al. Medicine (2017) 96:23 www.md-journal.com
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Moreover, 5-year survival rates based on these cutoff points were
listed in Supplemental Table 2, http://links.lww.com/MD/B723.
3.2. Meta-analysis
3.2.1. Comparative analysis. Eighteen publications that
reported serum levels of SP-A and (or) SP-D were included in
these analyses. We compared the serum levels of SP-A and (or)
SP-D of patients with IPF to patients with non-IPF ILD or
pulmonary infection, or healthy controls (Figs. 2 and 3).
Serum SP-A levels among patients with IPF were significantly
higher than patients with non-IPF ILD (SMD: 1.108 [0.584,
1.632], Z value=4.15, P< .001, I2=90.5%, P< .001); patients
with pulmonary infection (SMD: 1.320 [0.999, 1.640],Z value=
8.07, P< .001, I2=36.2%, P= .166); and healthy controls
(SMD: 2.802 [1.901, 3.702], Z value=6.10, P< .001, I2=
96.2%, P< .001; Fig. 2). The I2 values suggest high heterogeneity
across healthy and non-IPF ILD comparisons. Serum SP-A levels
in patients with ILD and pulmonary infections were significantly
higher than controls (SMD: 2.200 [1.627, 2.773]; 1.097 [0.420,
1.774], Supplemental Fig 1, http://links.lww.com/MD/B724).
These comparisons suggest a high level of heterogeneity (I2=
95.8%, 87.0%, respectively, with P< .001, Supplemental Fig 1,
http://links.lww.com/MD/B724). To further evaluate the cause of
heterogeneity, we repeated the serum SP-A level comparisons
in specific diseases. The SP-A levels were significantly higher
in patients with IPF than in patients with sarcoidosis and
pneumonia, but not collagen vascular disease-associated intersti-
tial pneumonia (SMD: 0.344 [0.158, 0.846], Z value=1.34,
P= .180; Table 2).
Serum SP-D levels in patients with IPF were significantly higher
than SP-D in patients with pulmonary infection (SMD: 1.308
[0.813, 1.803], Z value=5.18, P< .001; Fig. 3) and healthy
controls (SMD: 2.235 [1.739, 2.731], Z value=8.83, P< .001;
Fig. 3). There was no significant difference in SP-D levels between
patients with IPF and non-IPF ILD (SMD: 0.459 [0.000, 0.919],
Z value=1.96, P= .050; Fig. 3). Surfactant protein-D levels are
significantly elevated in patients with ILD (SMD: 1.935 [1.504,
2.367], Supplemental Fig 2, http://links.lww.com/MD/B724), as
well as pulmonary infections (SMD: 2.466 [0.558, 4.374],
Supplemental Fig. 2, http://links.lww.com/MD/B724). Further-
Figure 2. Serum SP-A levels comparisons between IPF and other groups (non-IPF ILD, pulmonary infections or healthy controls). Serum SP-A levels in IPF patients
were higher than non-IPF ILD patients (SMD: 1.108 [0.584, 1.632], Z value=4.15, P< .001), pulmonary infections (SMD: 1.320 [0.999, 1.640], Z value=8.07,
P< .001) or healthy controls (SMD: 2.802 [1.901, 3.702], Z value=6.10, P< .001).
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Figure 3. SerumSP-D levels comparisons between IPF and other groups (non-IPF ILD, pulmonary infections or healthy controls). Serum SP-D levels in IPF patients
were higher than pulmonary infections (SMD: 1.308 [0.813, 1.803], Z value=5.18, P< .001) or healthy controls (SMD: 2.235 [1.739, 2.731], Z value=8.83,
P< .001). However, there was no significant difference of serum SP-D levels between IPF and non-IPF ILD patients (SMD: 0.459 [-0.000, 0.919], Z value=1.96,
P= .050).
Table 2
Role of serum SP-A/D levels in specific disease comparisons.
SP-A/D and diseases Comparisons No. SMD SMD LL SMD UL Z P I2
SP-A
IPF vs sarcoidosis 4 183/248 1.647 1.242 2.052 7.97 <.001 0.607
IPF vs CVD-IP 3 56/29 0.344 -0.158 0.846 1.34 .180 0.156
IPF vs pneumonia 4 156/74 1.457 1.040 1.875 6.84 <.001 0.356
IPF (AE vs stable) 2 52/29 0.770 0.300 1.240 3.21 .001 0.000
SP-D
IPF vs sarcoidosis 4 199/264 1.582 0.993 2.172 5.26 <.001 0.844
IPF vs CVD-IP 5 169/112 0.360 -0.212 0.931 1.23 .218 0.752
IPF vs pneumonia 3 118/61 1.489 0.954 2.023 5.46 <.001 0.484
IPF (AE vs stable) 4 106/90 0.684 0.265 1.104 3.20 .001 0.425
AE= acute exacerbation, CVD-IP= collagen vascular disease-associated interstitial pneumonitis, IPF= idiopathic pulmonary fibrosis, LL= lower limit, UL=upper limit.
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more, we compared the serum SP-D level in specific diseases. The
SP-D serum level in patients with IPF patients was significantly
higher than in patients with sarcoidosis (SMD=1.582 [0.993,
2.172], Z value=5.26, P< .001; Table 2), and the heterogeneity
was high (I2=84.4%). There was no significant difference
between patients with collagen vascular disease-associated
interstitial pneumonia and IPF (SMD: 0.360 [0.212, 0.931],
Z value=1.23, P= .218; Table 2). Moreover, elevated SP-A and
SP-D might indicated AE of IPF (SP-A SMD: 0.770 [0.300,
1.240], SP-D SMD: 0.684 [0.265, 1.104]; Table 2). Only
Kakugawa’s research reported elevated SP-A and potentially
elevated SP-D level in AE phase compared to stable phase in the
same patients.[35]
3.2.2. Prognostic analysis. Seven publications were included to
evaluate the effect of serum levels of SP-A and SP-D on the death
of patients with IPF. A higher SP-A level was associated with a
significantly higher risk of death, and there was no heterogeneity
(pooled HR: 1.39 [1.10, 1.75], Z value=2.80, P= .005, I2=
0.0%; Fig. 4A). There was a significant association between
higher SP-D level and increased risk of death, without
heterogeneity (HR: 2.11 [1.60, 2.78], Z value=5.31, P< .001,
I2=0.0%; Fig. 4B). Sensitivity analysis indicated that no specific
study influenced the pooledHR (Supplemental Fig. 3, http://links.
lww.com/MD/B724).
No obvious asymmetry was observed in the funnel plot
regarding the association between SP-A and death (Egger’s test:
P= .388; Fig. 4C), indicating no evidence of publication bias.
Similar asymmetry was observed for the association between SP-
D and death (Egger’s test: P= .276; Fig. 4D).
3.3. Race subgroup analysis
Both Asian (SMD 2.849 [1.862, 3.836], P< .001) and Caucasian
(SMD 2.685 [0.832, 4.538], P= .005; Table 3) patients with IPF
had significantly higher serum levels of SP-A when compared
with healthy controls. Similar results were observed for SP-D
(Table 3). Significantly higher SP-A serum levels (SMD 1.355
[0.665, 2.044], P< .001) and SP-D (SMD 0.871 [0.202, 1.540],
P= .011) were identified in Caucasian patients with IPF, when
compared to Caucasian patients with non-IPF ILD. However, no
significant differences in serum levels of SP-D (SMD 0.150
[-0.401, 0.701], P= .593) were identified when Asian patients
with IPF were compared to Asian patients with non-IPF ILD
(Table 3). Higher levels of SP-A (pooled HR 1.336, 95% CI
[1.027, 1.738], P= .031) and SP-D (pooled HR 1.961, 95% CI
[1.299, 2.961], P= .001) were associated with increased risk of
death among Asian patients with IPF. In Caucasian patients with
IPF, a higher level of SP-D (pooled HR 2.243, 95% CI [1.547,
3.252], P< .001) was a risk factor for increasedmortality, while a
higher SP-A was not associated with increased mortality (pooled
HR 1.459, 95% CI [0.740, 2.879], P= .276).
4. Discussion
In this study, serum levels of SP-A could be used to differentiate
patients with IPF from patients with non-IPF ILD, pulmonary
Figure 4. Forest plot and funnel plot for the association between serum SP-A/D levels and IPF patients’ prognosis. (A) Forest plot for the role of serum SP-A levels in
IPF prognosis. HR and heterogeneity were shown (HR: 1.39 [1.10–1.75], Z value: 2.80, P= .005, I2=0.0%). P value ofQ statistic test was also presented (P= .656).
(B) Funnel plot for role of serum SP-A levels in IPF prognosis. No obvious asymmetry could be observed (Egger’s test: P= .388). (C) Forest plot for the role of serum
SP-D levels in IPF prognosis. HR and heterogeneity were shown (HR: 2.11 [1.60–2.78], Z value: 5.31, P< .001, I2=0.0%). P value of Q statistic test was also
presented (P= .771). 4D: funnel plot for role of serum SP-D levels in IPF prognosis. No obvious asymmetry could be observed (Egger’s test: P= .276).
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infection, and healthy controls. Serum SP-D levels could be used
to differentiate patients with IPF from those with pulmonary
infections and healthy controls, but not from patients with non-
IPF ILD. Among Caucasian patients, both SP-A and SP-D levels
differentiated patients with IPF from those with non-IPF ILD, and
healthy controls. However, among Asian patients, higher level of
SP-D differentiated patients with IPF only when compared to
healthy controls. SP-A and SP-D could predict prognosis. Patients
with IPF and elevated levels of SP-A had a 1.39-fold (95% CI
1.10, 1.75) increased risk of poor prognosis. Patients with IPF
and elevated levels of SP-D had 2.11-fold (95% CI 1.60, 2.78)
increased risk of poor prognosis. The cutoff points of SP-A (or SP-
D) were the same order of magnitude except particular research.
Different cutoff points may due to different calculation methods,
race, severity, and so on.
Higher SP-A and SP-D serum levels among patients with IPF
may be a result of genetic and environmental susceptibility.
Pulmonary fibrosis may occur in genetically susceptible individ-
uals after exposure to one of several environmental stressors.
These stressors cause abnormal surfactant synthesis, secretion,
and recycling, in both children and adults.[46] Serum levels of SP-
A and SP-D are significantly elevated in patients with IPF,
bacterial pneumonia, and tuberculosis, compared to the healthy
controls. Kati et al.[47] suggested that serum SP-D levels were
significantly higher in patients with IPF and submassive
pulmonary embolism than in controls and SP-D may have a
diagnostic role in sub-massive pulmonary embolism.
AE of IPF is characterized by an acute worsening of dyspnea,
with the potential of hypoxemic respiratory failure, and new or
progressive pulmonary infiltrates on radiologic images.[48] There
is a difference in levels of serum SP-A and SP-D between stable
and AE of IPF. In this study, we found that serum levels of SP-A
and SP-D increased significantly in an AE of IPF, when compared
to levels in stable IPF. Pathologically, it may result from
functional abnormalities of type II alveolar epithelial cells,
including endothelial cells injuries and coagulation abnormali-
ties.[49] Therefore, SP-A and SP-D, reflecting type II alveolar
epithelial cell injury and proliferation, will increase with an AE of
IPF. However, in clinical practice, the combination of serum SP-
A/SP-D with other predictors (eg, symptoms or HRCT) will
enhance diagnostic accuracy of AE.
Elevated SP-A and SP-D in patients with IPF is likely the result
of increased secretion by type II alveolar epithelial cells. An
increase in total number of type II cells, resulting from diffuse
hyperplasia, leads to increased leakage from the alveoli to the
interstitium, and decreased clearance from vascular compart-
ment. Selman and Pardo[50] reported that IPF was not an
inflammatory disorder, and that alveolar epithelial cell damage
and activation were a result of constant microscopic injury.
Hyperplasia of type II alveolar epithelial cells results in loss of
type I alveolar epithelial cells. In patients with IPF, Nishikiori
et al.[20] identified thickened matrix, near the alveolar space, and
capillary hyperplasia was detected using CD34.[51,52] These
capillaries were near the regenerated type II alveolar epithelial
cells, and were SP-A and SP-D positive. Surfactant proteins can
leak directly into the bloodstream through capillaries instead of
lymphatic ducts.
The blood-air barrier of lung comprises the alveolar epitheli-
um, alveolar epithelial basal layer, substantia propria, capillary
basement membrane, and capillary endothelial cells. Injury to
any part of the barrier will increase permeability, resulting in
leakage of SP-A and SP-D from the alveolus to the capillaries.
Barbas-Filho et al.[53] conducted a retrospective study including
55 patients with histologically confirmed IPF. Using electron
microscopy, they detected apoptosis in 89% of the patients with
IPF/UIP.
In animal experiments, alveolar epithelial cell death was
observed, and bleomycin was used to induce pulmonary
fibrosis.[54,55] Repeated injuries of alveolar epithelial cells
resulted in cell death, but the exact mechanism is unclear.
Angiotensin II and Fas signaling were associated with alveolar
epithelial cell death in bleomycin-induced lung injury.[56,57]
The inflammatory reaction may be involved in the pathogene-
sis of IPF. There is evidence of immune cell infiltration and
inflammatory cytokine production in patients with IPF. Carre
et al.[58] reported that the levels of interleukin-8 (IL-8) mRNA in
alveolar macrophages, and the level of IL-8 protein in
bronchoalveolar lavage, were significantly higher in patients
with IPF than in healthy subjects. Both IL-8 mRNA and IL-8
protein were associated with disease severity. Other cytokines
and chemokines, including tumor necrosis factor alpha (TNF-a),
IL-1b, IL-4, and IL-5, are overexpressed in patients with
IPF.[59,60] In an inflammatory environment, capillary permeabili-
ty increases, and SP-A and SP-D leakage from the alveolus to the
capillary increases. Mechanisms include damage of the junction
of capillary endothelial cells, dysfunction of endothelial cell signal
transduction, and release of inflammatory cytokines.
In addition, the concentration difference between alveolar
airspace and the blood and reduction of SP clearance contribute
to the elevation of the serum levels of SP-A and SP-D. IPF and
non-IPF ILD have a similar pathogenesis.We found no significant
differences in the serum concentration of SP-A and SP-D between
patients with IPF and non-IPF ILD (including progressive
systemic sclerosis, pulmonary alveolar proteinosis, idiopathic
Table 3
Race subgroups analysis in IPF comparisons and prognosis.
Asian Caucasian
Comparisons n SMD/HR (95% CI) P n SMD/HR (95% CI) P
SP-A
IPF vs healthy controls 7 2.849 (1.862–3.836) <.001 4 2.685 (0.832–4.538) .005
IPF vs Non-IPF ILD 8 0.966 (0.123–1.810) .025 4 1.355 (0.665–2.044) <.001
High vs low SP-A in IPF prognosis 3 1.336 (1.027–1.738) .031 2 1.459 (0.740–2.879) .276
SP-D
IPF vs healthy controls 5 2.349 (1.613–3.085) <.001 7 2.164 (1.448–2.881) <.001
IPF vs non-IPF ILD 11 0.150 (-0.401 to 0.701) .593 8 0.871 (0.202–1.540) .011
High vs low SP-D in IPF prognosis 3 1.961 (1.299–2.961) .001 3 2.243 (1.547–3.252) <.001
CI= confidence Interval, HR=hazard Ratio, ILD= interstitial lung disease, IPF= idiopathic pulmonary fibrosis, SMD= standard mean difference.
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nonspecific interstitial pneumonia, and sarcoidosis). When
comparing patients with IPF and sarcoidosis, there is no
difference in SP-A, but there is a difference in SP-D, and the
reason is unclear.
The median survival of patients with IPF patients is three years,
indicating a poor prognosis.[61] Despite the potential use of SP-A/
SP-D as diagnostic aids, the diagnosis of IPF is confirmed by
surgical biopsy or HRCT. According to guidelines, serum SP-A/
SP-D cannot replace biopsy or HRCT.[4] However, SP-A/SP-D
has the following advantages. First, SP-A/SP-D serum levels could
be preliminarily evaluated in patients apprehensive of traumatic
examination and surgery. Second, image findings in HRCT are
not typical, which complicate the diagnosis, and may delay early
diagnosis and treatment. Other physiological measurements have
been suggested for predicting the severity and prognosis of
patients with IPF, including the GAP index[62] (gender, age, and 2
lung physiology variables, FVC and DLco) and the CPI[13]
(composite physiologic index). Ley et al.[62] reported that the
GAP index and staging system and the GAP calculator were
better predictors of morality in patients with IPF than previously
developed prediction models. This method has important utility
for both clinical practice and trials. Our analyses indicate that the
use of serum biomarkers should not replace the existing
physiological measurements for predicting prognosis, as each
method has its own limitation. Combining these methods (eg,
GAP models, HRCT, and serum biomarkers) could increase the
accuracy and sensitivity in determining the prognosis of patients
with IPF. Several studies suggested that serum SP-A and/or SP-D
can combine with existing physiologic parameters to enhance the
ability of predicting survival. Those clinical variables include age,
smoking status, FVC, Dlco, and so on.[27,44]
Our study still has several limitations. Although we tried to
control the study quality by the Newcastle–Ottawa quality
assessment scale, the included studies were all retrospective,
which intrinsically presents difficulty in causality inference. Only
Chinese and English articles were included in this analysis.
Statistical heterogeneity was prevalent among our included
studies in the overall analyses. The cutoff of high versus low
serum levels was inconsistent among the included publications. In
the articles included, 3 did not provide a specific cutoff value, and
we were unable to obtain the original data. Among the cutoff
values provided by the author, the numbers in each article were
different.
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